STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting STAT3 via siRNA applications seems to be a potent strategy for improving novel CML therapeutics as overcoming nilotinib TKI resistance, and re-sensitization of nilotinib in resistant cells could be mediated by inducing apoptosis and modulating cell energy phenotype.